Page 402 - Read Online

Page 14 of 16 Pearce et al. Neuroimmunol Neuroinflammation 2018;5:47 I http://dx.doi.org/10.20517/2347-8659.2018.46

3. Carson MJ, Doose JM, Melchior B, Schmid CD, Ploix CC. CNS immune privilege: hiding in plain sight. Immunol Rev 2006;213:48-65.
4. Weller RO, Galea I, Carare RO, Minagar A. Pathophysiology of the lymphatic drainage of the central nervous system: implications for
pathogenesis and therapy of multiple sclerosis. Pathophysiology 2010;17:295-306.
5. Jack AS, Lu JQ. Immune cell infiltrates in the central nervous system tumors. Austin Neurosurgery Open Access 2015;2:1024.
6. Wilson EH, Weninger W, Hunter CA. Trafficking of immune cells in the central nervous system. J Clin Invest 2010;120:1368-79.
7. Sagar D, Foss C, El Baz R, Pomper MG, Khan ZK, et al. Mechanisms of dendritic cell trafficking across the blood-brain barrier. J
Neuroimmune Pharmacol 2012;7:74-94.
8. Han S, Zhang C, Li Q, Dong J, Liu Y, et al. Tumour-infiltrating CD4(+) and CD8(+) lymphocytes as predictors of clinical outcome in
glioma. Br J Cancer 2014;110:2560-8.
9. Skwarczynski M, Toth I. Peptide-based synthetic vaccines. Chem Sci 2016;7:842-54.
10. Golubovskaya V, Wu L. Different subsets of T cells, memory, effector functions, and CAR-T immunotherapy. Cancers (Basel) 2016;
doi: 10.3390/cancers8030036.
11. Ostroumov D, Fekete-Drimusz N, Saborowski M, Kühnel F, Woller N. CD4 and CD8 T lymphocyte interplay in controlling tumor
growth. Cell Mol Life Sci 2018;75:689-713.
12. Hashimoto M, Kamphorst AO, Im SJ, Kissick HT, Pillai RN, et al. CD8 T cell exhaustion in chronic infection and cancer: opportunities
for interventions. Annu Rev Med 2018;69:301-18.
13. Gust J, Hay KA, Hanafi LA, Li D, Myerson D, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after
adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov 2017;7:1404-19.
14. Zhang E, Gu J, Xu H. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors. Mol Cancer 2018;17:7.
15. Kueberuwa G, Kalaitsidou M, Cheadle E, Hawkins RE, Gilham DE. CD19 CAR T cells expressing IL-12 eradicate lymphoma in fully
lymphoreplete mice through induction of host immunity. Mol Ther Oncolytics 2017;8:41-51.
16. Gan HK, Cvrljevic AN, Johns TG. The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered. FEBS J
2013;280:5350-70.
17. O’Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, et al. A single dose of peripherally infused EGFRvIII-directed CAR
T cellsT-cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med 2017; doi:
10.1126/scitranslmed.aaa0984.
18. Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, et al. Regression of glioblastoma after chimeric antigen receptor T-Cell therapy. N
Engl J Med 2016;375:2561-9.
19. Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-
enhanced T cells in myeloma and melanoma. Blood 2013;122:863-71.
20. Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, et al. T cells targeting carcinoembryonic antigen can mediate regression
of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 2011;19:620-6.
21. Davila ML, Riviere I, Wang X, Bartido S, Park J, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute
lymphoblastic leukemia. Sci Transl Med 2014;6:224ra25.
22. Maude SL, Barrett D, Teachey DT, Grupp SA. Managing cytokine release syndrome associated with novel T cell-engaging therapies.
Cancer J 2014;20:119-22.
23. Baum C, Düllmann J, Li Z, Fehse B, Meyer J, et al. Side effects of retroviral gene transfer into hematopoietic stem cells. Blood
2003;101:2099-114.
24. Modlich U, Navarro S, Zychlinski D, Maetzig T, Knoess S, et al. Insertional transformation of hematopoietic cells by self-inactivating
lentiviral and gammaretroviral vectors. Mol Ther 2009; 17:1919-28.
25. Morita D, Nishio N, Saito S, Tanaka M, Kawashima N, et al. Enhanced expression of anti-CD19 chimeric antigen receptor in piggyBac
transposon-engineered T cells. Mol Ther Methods Clin Dev 2017;8:131-40.
26. Monjezi R, Miskey C, Gogishvili T, Schleef M, Schmeer M, et al. Enhanced CAR T-cell engineering using non-viral Sleeping Beauty
transposition from minicircle vectors. Leukemia 2016;31;186-94.
27. Kebriaei P, Singh H, Huls MH, Figliola MJ, Bassett R, et al. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T
cells. J Clin Invest 2016;126:3363-76.
28. Martinet L, Smyth MJ. Balancing natural killer cell activation through paired receptors. Nat Rev Immunol 2015;15;243-54.
29. Krasnova Y, Putz EM, Smyth MJ, Souza-Fonseca-Guimaraes F. Bench to bedside: NK cells and control of metastasis. Clin Immunol
2017;177:50-9.
30. Hayakawa Y, Huntington ND, Nutt SL, Smyth MJ. Functional subsets of mouse natural killer cells. Immunol Rev 2006;214:47-55.
31. Kmiecik J, Zimmer J, Chekenya M. Natural killer cells in intracranial neoplasms: presence and therapeutic efficacy against brain
tumours. J Neurooncol 2014;116:1-9.
32. McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, et al. Randomized phase III trial of high-dose interleukin-2 versus
subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005;23:133-41.
33. Steele N, Anthony A, Saunders M, Esmarck B, Ehrnrooth E, et al. A phase 1 trial of recombinant human IL-21 in combination with
cetuximab in patients with metastatic colorectal cancer. Br J Cancer 2012;106:793-8.
34. Davis ID, Skrumsager BK, Cebon J, Nicholaou T, Barlow JW, et al. An open-label, two-arm, phase I trial of recombinant human
interleukin-21 in patients with metastatic melanoma. Clin Cancer Res 2007;13:3630-6.
35. Conlon KC, Lugli E, Welles HC, Rosenberg SA, Fojo AT, et al. Redistribution, hyperproliferation, activation of natural killer cells and
CD8 T-cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J
Clin Oncol 2015;33:74-82.
36. Ni J, Miller M, Stojanovic A, Garbi N, Cerwenka A. Sustained effector function of IL- 12/15/18-preactivated NK cells against
established tumors. J Exp Med 2012;209:2351-65.